EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study

John R Ingram iD, Janine Bates iD, Rebecca Cannings-John iD, Fiona Collier iD, Judith Evans, Angela Gibbons iD, Ceri Harris iD, Laura Howells iD, Kerenza Hood iD, Rachel Howes iD, Paul Leighton iD, Muhammad Riaz iD und 4 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad388 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von John R Ingram und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection & Immunity. Hauptthemen laut MEDLINE: Clindamycin, Hidradenitis Suppurativa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Health Technology Assessment, Department of Health and Social Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but are rarely offered in the UK.

Objectives

To describe current UK HS management pathways and influencing factors to inform the design of future randomized controlled trials (RCTs).

Methods

THESEUS was a nonrandomized 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200 mg daily; oral clindamycin and rifampicin both 300 mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing; and conventional surgery. The primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. The secondary outcomes were the proportion of participants selecting each intervention as their final treatment option; the proportion who switch treatments; treatment fidelity; and attrition rates. THESEUS was prospectively registered on the ISRCTN registry: ISRCTN69985145.

Results

The recruitment target of 150 participants was met after 18 months, in July 2021, with two pauses due to the COVID-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36 years, 81% female, 20% non-White, 64% current or ex-smokers, 86% body mass index ≥ 25, 68% with moderate disease, 19% with severe disease and 13% with mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after 3 and 6 months, respectively. Concordance with doxycycline was 52% after 3 months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing, respectively, after 3 months. Uptake of conventional surgery was too small to characterize the intervention. Switching treatment was uncommon and there were no serious adverse events.

Conclusions

THESEUS has established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClindamycinHidradenitis SuppurativaFemaleHumansAdultMaleRifampinDoxycyclineCohort Studies

Substanzen

ClindamycinRifampinDoxycycline

Autor:innen und Institutionen

  • Division of Infection & Immunity.
  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, UK.
  • NHS Forth Valley, Stirling, Scotland, UK.
  • Public contributors.
  • Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
  • Department of Plastic Surgery, John Radcliffe Hospital, Oxford NHS Trust, Oxford, UK.

ORCID-Profile: John R Ingram, Janine Bates, Rebecca Cannings-John, Fiona Collier, Angela Gibbons, Ceri Harris, Laura Howells, Kerenza Hood, Rachel Howes, Paul Leighton, Muhammad Riaz, Jeremy Rodrigues, Helen Stanton, Kim S Thomas, Emma Thomas-Jones

Förderung

  • National Institute for Health Research
  • Health Technology Assessment
  • Department of Health and Social Care

Zitieren

APA

Ingram, J. R., Bates, J., Cannings-John, R., Collier, F., Evans, J., Gibbons, A., Harris, C., Howells, L., Hood, K., Howes, R., Leighton, P., Riaz, M., Rodrigues, J., Stanton, H., Thomas, K. S., & Thomas-Jones, E. (2024). Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad388

Vancouver

Ingram JR, Bates J, Cannings-John R, Collier F, Evans J, Gibbons A, et al. Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad388

BibTeX
@article{Ingram2024,
  author = {Ingram, John R and Bates, Janine and Cannings-John, Rebecca and Collier, Fiona and Evans, Judith and Gibbons, Angela and Harris, Ceri and Howells, Laura and Hood, Kerenza and Howes, Rachel and Leighton, Paul and Riaz, Muhammad and Rodrigues, Jeremy and Stanton, Helen and Thomas, Kim S and Thomas-Jones, Emma},
  title = {Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad388}
}
Kostenlos starten →